Artal Group S.A. Mirati Therapeutics, Inc. Call Options Transaction History

Artal Group S.A.

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 09, 2024	SELL	$41.99 - $62.38 $8.4 Million - $12.5 Million	-200,000 Reduced 28.57%	500,000 $29.4 Million
Q3 2023 Nov 13, 2023	BUY	$27.8 - $45.35 $12.5 Million - $20.4 Million	450,000 Added 180.0%	700,000 $30.5 Million
Q2 2023 Aug 11, 2023	BUY	$36.13 - $49.49 $9.03 Million - $12.4 Million	250,000 New	250,000 $9.03 Million
Q4 2022 Feb 13, 2023	BUY	$41.27 - $98.62 $20.6 Million - $49.3 Million	500,000 New	500,000 $22.7 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.